In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
Manufacturing problems hindering production of MedImmune's
intranasal flu vaccine FluMist have finally been resolved at the
company's Liverpool, UK facility, with doses on track to be
available for this year's flu season.
MedImmune has embarked on an expansion of its biologics
manufacturing facility in Frederick, Maryland, to ramp up its cell
culture production capacity, as several of its monoclonal
antibodies (MAbs) approach commercialisation.
In a landmark decision that will speed up the manufacturing of
influenza vaccines, the US Food and Drug Administration (FDA) has
approved the use of reverse genetics technology in the production
of MedImmune's seasonal intranasal...
